In vivo quantification of central phosphodiesterase 7
- Conditions
- Health Condition
- Registration Number
- JPRN-jRCTs031190054
- Lead Sponsor
- Tagai Kenji
- Brief Summary
The distribution of [11C]MTP38 is consistent with that of PDE7, and kinetic analysis using arterial blood samples showed that it could be quantified by the reference tissue method, indicating that it is a promising ligand for clinical use.Besides, the investigation in combination with MRI suggested that it is useful for voxel-based analysis and applied analysis with MRI.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Male
- Target Recruitment
- 7
Healthy male subjects
1.Subjects who do not have ability to make informed consent.
2. Subjects with any psychiatric disorder or subjects with severe physical complication.
3. Subjects who currently smokes.
4. Subjects with any organic brain disorder.
5. Subjects with metallic medical device in the body.
6. Subjects with tattoo.
7. Subjects with severe claustrophobia.
8. Subjects with a history of allergy to heparin and local anesthetics.
9. Subjects who are taking an anticoagulant.
10. Subjects who has participated in other study in recent 6 months.
11. Subjects who has participated in blood donation in recent 12 weeks.
12. Subjects who is considered to be inappropriate to participate in the study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method